{"filings":[{"id":1967802,"accession_number":"0001628280-26-051045","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2026-07-30T20:06:54+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q2 revenue $103.5M (+20% YoY); raises FY2026 guidance to $365-375M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $103.5M vs $86.2M YoY; net loss $2.1M (incl. $11.6M stock comp) vs net income $4.5M.","Core test reports (DecisionDx-Melanoma, TissueCypher) up 32% YoY; TissueCypher reports surged 63% to 14,988.","Raises FY2026 revenue guidance to $365-375M from $345-355M; expects positive Adjusted EBITDA in Q3, Q4, and full year.","Adjusted EBITDA $12.4M vs $10.4M; cash $266.8M.","AdvanceAD-Tx test received NYSDOH approval; first patient enrolled in DETECT-AD study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":746881,"accession_number":"0001628280-26-039189","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2026-05-29T20:14:42+00:00","items":["5.07"],"status":"ready","headline":"Castle Biosciences stockholders elect three Class I directors and ratify KPMG as auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ellen Goldberg, Miles D. Harrison, and Tiffany P. Olson elected as Class I directors to serve until 2029 annual meeting.","KPMG LLP ratified as independent auditor for FY 2026 with 24,531,366 for, 445,666 against, 12,187 abstain.","Advisory vote on named executive officer compensation approved: 21,280,180 for, 1,281,394 against, 11,857 abstain.","Non-employee director compensation policy approved: 21,394,330 for, 1,130,133 against, 48,968 abstain.","All four proposals passed with requisite votes; broker non-votes of 2,415,788 on director elections and advisory/compensation items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92918,"accession_number":"0001628280-26-031255","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q1 revenue $83.7M; core tests +36%; raises FY guidance to $345-355M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $83.7M vs $88.0M Q1 2025; core test reports +36% YoY (DecisionDx-Melanoma +16%, TissueCypher +58%).","Net loss improved to $14.5M ($0.49/share) from $25.8M ($0.90); adjusted EBITDA -$5.1M vs +$13.0M.","Raises FY2026 revenue guidance to $345-355M from $340-350M; cash & investments $261.7M.","Gross margin 73% (adj. 76%) vs 49% (adj. 81%) prior year, which included $20.1M amortization acceleration.","Operating cash use $22.1M includes $28.8M in one-time bonus/benefit payments not expected to recur in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":83679000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104149,"accession_number":"0001628280-26-012263","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences FY2025 revenue up 4% to $344M, net loss of $24.2M vs income of $18.2M in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $344.2M (+4% YoY); excluding discontinued tests growth 34%. Core test reports (DecisionDx-Melanoma, TissueCypher) +37%.","Q4 revenue $87.0M (+1%); core reports +42%. TissueCypher reports up 86% in FY2025.","Net loss $24.2M ($0.83 loss per share) vs net income $18.2M ($0.66 EPS) in 2024. Adj. net loss per share $0.14.","Adjusted EBITDA $44.0M (FY2025) vs $75.0M (2024); net cash from ops $64.3M; cash & securities $299.5M at year-end.","2026 revenue guidance $340-350M; AdvanceAD-Tx limited launch; multiple publications support test utility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":344229000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104148,"accession_number":"0001628280-26-001909","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences expects 2025 revenue >$340M, above guidance; core test volumes up 37% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2025 total revenue >$340M, above guided range of $327-335M.","Q4 core test reports (DecisionDx-Melanoma, TissueCypher) +42% YoY.","DecisionDx-Melanoma Q4: 10,022 reports; TissueCypher Q4: 11,803 reports.","Year-end cash + marketable securities ~$300M.","AdvanceAD-Tx launched Nov 2025; >50% of initial clinicians ordered in first 5 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":344229000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120416,"accession_number":"0001628280-25-048248","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q3 revenue $83M, raises FY2025 guidance to $327-335M; launches AdvanceAD-Tx test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $83.0M (Q3 2025) vs $85.8M YoY; net loss $0.5M vs net income $2.3M.","Total test reports 26,841; DecisionDx-Melanoma and TissueCypher each exceeded 10,000 tests in a quarter for first time.","Full-year 2025 revenue guidance raised to $327-335M from $310-320M.","Launched AdvanceAD-Tx, a GEP test to guide systemic treatment for moderate-to-severe atopic dermatitis.","Non-dermatologic revenue up 67% YoY; adjusted EBITDA $9.2M vs $21.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":257219000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136996,"accession_number":"0001447362-25-000099","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Castle Biosciences adopts amended bylaws with changes to meeting procedures and governance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted amended and restated bylaws effective August 5, 2025, modifying quorum, advance notice, and proxy rules.","Advance notice window for stockholder proposals widened: meeting delayed >70 days (previously 30) triggers alternative deadline.","Quorum changed from majority of outstanding shares to majority of voting power; default approval threshold now majority of votes cast.","Universal proxy rules under Rule 14a-19 incorporated; stockholder nominees limited to number of directors to be elected.","Indemnification obligations expanded to maximum extent allowed by law; mandatory advancement of expenses clarified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136995,"accession_number":"0001447362-25-000096","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q2 revenue $86.2M, raises FY2025 guidance; core test volumes up 33% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $86.2M (vs $87.0M); adjusted revenue $86.2M. Core tests (DecisionDx-Melanoma, TissueCypher) volumes up 33% YoY.","TissueCypher test reports nearly doubled to 9,170 (from 4,782); DecisionDx-Melanoma up 4% to 9,981.","Raising FY2025 total revenue guidance to $310-320M from $287-297M, citing strong core test performance.","Net income $4.5M ($0.16 diluted EPS) vs $8.9M ($0.32) YoY; adjusted EBITDA $10.4M vs $21.5M.","FDA Breakthrough Device designation for DecisionDx-Melanoma; closed Previse acquisition and SciBase collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":174176000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154276,"accession_number":"0001447362-25-000085","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Castle Biosciences shareholders approve officer exculpation charter amendment; re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to certificate of incorporation to limit officer liability per Delaware law, effective May 22, 2025.","Re-elected Class III directors Kimberlee S. Caple, G. Bradley Cole, and Derek J. Maetzold to terms expiring 2028.","Ratified KPMG as independent auditor for FY2025 with 23.7M votes for, 20.8K against.","Approved advisory say-on-pay proposal with 20.0M for, 1.3M against, 43K abstain.","All proposals passed with overwhelming support; broker non-votes noted for director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154275,"accession_number":"0001447362-25-000068","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Q1 revenue $88M (+21% YoY), raises FY guidance to $287-297M, acquires Previse","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $88.0M (+21% YoY); total test reports 24,402 (+17%); core driver reports +33% YoY.","Net loss $(0.90) per share incl. $20.1M amortization acceleration; adjusted net loss $(0.20); Adj. EBITDA $13.0M.","FY 2025 revenue guidance raised to $287-297M from prior $280-295M.","Signed definitive agreement to acquire Previse, a GI health company focused on esophageal cancer; no terms disclosed.","DecisionDx-Melanoma surpassed 200,000 test orders; IDgenetix test to be discontinued effective May 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":87988000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172862,"accession_number":"0001447362-25-000030","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences FY 2024 revenue up 51% to $332M, net income $18.2M vs loss; 2025 outlook $280-295M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 revenue $332.1M (+51% YoY); test reports 96,071 (+36% YoY).","Net income $18.2M (incl. $50.3M stock comp) vs net loss $57.5M in 2023.","Adjusted EBITDA $75.0M vs -$4.4M in 2023; cash $293.1M, up $50M.","TissueCypher Barrett's Esophagus test reports surged 130% to 20,956; dermatology reports up 17%.","2025 revenue guidance $280-295M, below 2024 actual but achieved prior 2025 target a year early."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":332069000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172861,"accession_number":"0001447362-25-000012","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences expects 2024 revenue at least $330M (≥50% growth); Medicare non-covers DecisionDx-SCC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 revenue expected to meet or exceed top of guidance range $320-330M, at least 50% growth over 2023.","Delivered 96,071 total test reports in 2024, up 36% YoY; TissueCypher Barrett's Esophagus test grew 130%.","Year-end 2024 cash, cash equivalents and marketable securities approximately $293M.","Medicare contractor Novitas finalized non-coverage for DecisionDx-SCC test on January 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":332069000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189869,"accession_number":"0001447362-24-000168","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q3 revenue up 39% to $85.8M; raises FY2024 guidance to $320-330M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $85.8M (+39% YoY); net income $2.3M vs. ($6.9M) loss; adj. EBITDA $21.6M vs $6.6M.","Total test reports 26,010 (+41% YoY); TissueCypher up 115%, IDgenetix up 81%, DecisionDx-SCC up 49%.","Raises full-year 2024 revenue guidance to $320-330M from prior $275-300M.","Cash, equivalents and marketable securities $279.8M at Sept 30, 2024.","Q3 operating cash flow $23.3M vs $5.0M prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":245758000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206382,"accession_number":"0001447362-24-000121","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.","Total test reports 25,102 (+49% YoY); TissueCypher +230%, DecisionDx-SCC +60%.","Raises FY2024 revenue guidance to $275-300M from prior $255-265M.","Adjusted EBITDA $21.5M vs ($5.3M) in Q2 2023; gross margin 81%.","Cash and investments $259.7M; net cash from operations $24.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":159976000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223500,"accession_number":"0001447362-24-000072","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Castle Biosciences stockholders elect directors, ratify KPMG, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daniel M. Bradbury elected as Class II director with 15.95M for, 5.28M withhold; Rodney Cotton with 21.11M for, 117K withhold.","Ratification of KPMG as independent auditor for FY2024: 22.27M for, 184K against, 17K abstain.","Advisory vote on executive compensation approved: 20.62M for, 306K against, 299K abstain, 1.24M broker non-votes.","Annual meeting held on May 23, 2024; all three proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223499,"accession_number":"0001447362-24-000059","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q1 revenue $73M (+74% YoY); raises FY2024 guidance to $255-265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $73.0M (+74% YoY); adjusted revenue $71.3M (+64% YoY).","Net loss narrowed to $2.5M from $29.2M; adjusted EBITDA improved to $10.5M from -$15.1M.","Total test reports +40% to 20,888; TissueCypher +148%, IDgenetix +90%.","FY2024 revenue guidance raised to $255-265M from prior $235-240M.","Cash & marketable securities $239.2M; gross margin 78% (adj. 81%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":72974000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242946,"accession_number":"0001193125-24-078933","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Castle Biosciences secures $35M SVB loan facility; appoints Rodney Cotton to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Loan Agreement with Silicon Valley Bank for $10M drawn, $25M additional available.","Proceeds to fund future HQ office building and working capital; interest at WSJ Prime +0.25% (floor 6%).","Interest-only through Nov 2025 (extendable to Nov 2026); maturity Nov 2028; secured by most assets.","Director Mara Aspinall not standing for re-election; Rodney Cotton (ex-Roche) appointed as Class II director.","Cotton receives initial RSU valued at $350K vesting over 3 years plus annual $45K cash retainer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242945,"accession_number":"0001447362-24-000016","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences FY2023 revenue $219.8M (+60%); Q4 $66.1M; guides 2024 $235-240M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 revenue $219.8M (+60% YoY); total test reports 70,429 (+59%). Q4 revenue $66.1M (+72% YoY).","Net loss $57.5M in 2023 vs. $67.1M in 2022; Q4 net loss $2.6M vs. $20.6M. Adjusted EBITDA $(4.4)M year, $9.4M Q4.","Cash, cash equivalents and marketable securities $243.1M at Dec 31, 2023.","TissueCypher test reports +328% YoY; DecisionDx-SCC +92%; IDgenetix +236%.","2024 revenue guidance: $235-240 million; management cites strong commercial momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":219788000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242944,"accession_number":"0001447362-24-000006","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences expects 2023 revenue >$210M, exceeding guidance; test volume +59%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expects 2023 total revenue >$210M, at least 53% growth over 2022, surpassing prior guidance floor of $200M.","Delivered 70,429 total test reports in 2023, up 59% YoY; Q4 reports 20,284, up 60% YoY.","TissueCypher Barrett's Esophagus test reports surged 328% YoY in 2023; IDgenetix up 236%.","Year-end cash, equivalents and short-term investments expected ~$243M.","Preliminary results, subject to audit completion; final results may differ."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":219788000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260311,"accession_number":"0001193125-23-274634","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Castle Biosciences adopts Severance and Change in Control Plan for top executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan adopted Nov 3, 2023; covers CEO Maetzold, CFO Stokes, CCO Juvenal, COO Oelschlager.","On CIC termination: CEO gets 36 months salary + 300% target bonus; others get 12 months salary + prior year bonus.","On non-CIC termination: CEO gets 18 months salary + 150% target bonus; others get 12 months salary + 100% target bonus.","Equity acceleration: 100% on CIC termination; pro-rata for 12/18 months on non-CIC termination.","Plan replaces prior severance benefits under employment agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260310,"accession_number":"0001447362-23-000146","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q3 revenue $61.5M (+66% YoY), raises FY2023 guidance to at least $200M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $61.5M, up 66% YoY; adjusted revenue $60.6M, up 63%.","Total test reports 18,409 (+52% YoY); DecisionDx-Melanoma 8,559 (+16%), TissueCypher 2,829 (+310%).","Net loss narrowed to $(6.9)M from $(20.2)M; adjusted EBITDA $6.6M vs $(9.6)M.","Raised FY2023 revenue guidance to at least $200M from at least $180M.","Operating cash flow positive $5.0M; cash $229.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":153668000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277604,"accession_number":"0001447362-23-000127","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q2 revenue $50.1M (+44% YoY); raises FY 2023 guidance to at least $180M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $50.1M (+44% YoY); adjusted revenue $50.2M (+47%).","Total test reports 16,820 (+52%); DecisionDx-SCC +99%, TissueCypher +311%, IDgenetix +224%.","Net loss $(18.8)M includes $12.8M stock comp; adjusted EBITDA improves to $(5.3)M from $(11.2)M.","Raises 2023 revenue guidance to at least $180M from prior $170-180M.","Cash and investments $225.5M; net operating cash use improved to $3.8M from $9.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":92175000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295589,"accession_number":"0001447362-23-000097","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Castle Biosciences reaffirms FY2023 revenue guidance of $170-180M and 2025 targets","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reaffirms FY2023 total revenue guidance of $170-$180M.","Reaffirms 2025 total revenue target of $255-$330M.","Reaffirms target to achieve net operating cash flow positivity by 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295588,"accession_number":"0001447362-23-000095","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Castle Biosciences shareholders reject say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Advisory vote on named executive officer compensation failed: 8.96M for, 11.10M against, 41.7K abstain, 1.73M broker non-votes.","Three Class I directors elected: Ellen Goldberg (13.79M for), Miles D. Harrison (13.51M for), Tiffany P. Olson (18.35M for).","Ratification of KPMG as independent auditor approved: 21.71M for, 94.3K against, 35.8K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295587,"accession_number":"0001447362-23-000065","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q1 revenue up 57% to $42M; reaffirms FY 2023 guidance $170-180M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Delivered 14,916 total test reports (+73% YoY); DecisionDx-Melanoma 7,583 (+26%), DecisionDx-SCC 2,411 (+111%).","Revenue $42.0M (+57% YoY); adjusted revenue $43.4M (+65%); net loss ($29.2M) vs ($24.6M) prior year.","Gross margin 70.5% (adjusted 76.5%); cash & marketable securities $232.1M as of March 31, 2023.","Reaffirms full-year 2023 revenue guidance of $170-180M; Q1 cash use includes $17.7M non-recurring bonus/benefit payments."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":42037000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316117,"accession_number":"0001447362-23-000036","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences FY2022 revenue $137M (+46% YoY); guides FY2023 revenue $170-180M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenue $137.0M, up 46% from $94.1M; test reports 44,419, up 58%.","Q4 2022 revenue $38.3M (+53% YoY); test reports 12,644 (+53%).","Net loss $67.1M (incl. $36.3M stock compensation) vs $31.3M loss in 2021.","Adjusted EBITDA -$42.6M vs -$14.9M; cash and investments $258.6M at year-end.","FY2023 revenue outlook $170-180M; reaffirms 2025 targets of $255-330M revenue and cash flow positivity."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":137039000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316116,"accession_number":"0001447362-23-000009","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2023-01-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Castle Biosciences adopts retirement policy accelerating equity vesting for eligible employees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Policy covers VP-level and above employees retiring after age 60 with 5+ years of service.","Accelerates vesting of time- and performance-based equity awards scheduled to vest within set periods (up to 24 months for CEO).","Extends post-retirement exercise period to 12 months for vested time-based awards.","Requires 90-day retirement notice (180 days for CEO) and full release of claims.","Effective January 13, 2023; designed to encourage long-term retention of senior leaders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316115,"accession_number":"0001447362-23-000007","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences expects 2022 revenue to exceed top end of $132-137M guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total test reports in 2022: 44,338, up 58% YoY from 28,118.","DecisionDx-Melanoma volume 27,797 (+37% YoY); DecisionDx-SCC 5,966 (+70% YoY).","Year-end cash & short-term investments ~$259M ($123M cash + $136M short-term).","Q4 2022 test reports 12,563 (+52% YoY from 8,242); TissueCypher and IDgenetix newly contributed."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":137039000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334435,"accession_number":"0001447362-22-000203","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-12-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Castle Biosciences adopts 2022 Inducement Plan for 350,000 shares to attract new employees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved 2022 Inducement Plan reserving 350,000 shares of common stock for new hires as material inducement.","Plan adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4).","Awards include nonstatutory stock options, SARs, restricted stock, RSUs, and performance-based awards.","Terms substantially similar to the company's stockholder-approved 2019 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334434,"accession_number":"0001447362-22-000199","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Castle Biosciences grants time-based and performance-based RSUs to CEO, CFO, CCO, COO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant of 133,983 time-based and 133,982 performance-based RSUs to CEO Derek J. Maetzold.","CFO Frank Stokes received 58,467 time-based and 19,489 performance-based RSUs.","CCO Tobin Juvenal and COO Kristen Oelschlager each received 63,844 time-based and 21,281 performance-based RSUs.","Time-based RSUs vest in four equal annual installments; performance-based vest on achievement of financial metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334433,"accession_number":"0001447362-22-000171","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q3 revenue $37M (+58% YoY), raises 2022 guidance to $132-137M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $37.0M (+58% YoY); total test reports 12,114 (+57% YoY).","Net loss $(20.2)M vs $(11.8)M; adjusted EBITDA $(8.3)M vs $(5.5)M.","2022 revenue guidance raised to $132-137M from $130-135M.","Three-year target: FY2025 revenue $255-330M; positive net operating cash flow by 2025.","Acquisitions TissueCypher (690 reports) and IDgenetix (1,208 reports) contributed in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":98701000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351850,"accession_number":"0001447362-22-000135","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Q2 revenue $34.8M (+53%); raises 2022 guidance to $130-135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total test reports 11,034 (+57% YoY); skin cancer GEP volume up 44% YoY.","Net loss $(1.6)M improved from $(8.8)M; adjusted EBITDA $(10.9)M vs $(3.4)M.","2022 revenue guidance raised to $130-135M from $118-123M; cash $273M.","DecisionDx-Melanoma test linked to 27% improvement in melanoma-specific survival in NCI collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":61690000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369288,"accession_number":"0001447362-22-000109","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders reject advisory say-on-pay proposal at Castle Biosciences annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Say-on-pay failed: 8,331,458 For vs 11,985,739 Against; broker non-votes 1,869,015.","Class III directors Kimberlee S. Caple, G. Bradley Cole, and Derek J. Maetzold re-elected.","Ratified KPMG LLP as independent auditor for fiscal year 2022 (22,499,340 For).","Advisory vote on frequency: 20,368,320 preferred 1 year; board will hold annual say-on-pay votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369287,"accession_number":"0001447362-22-000092","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Castle Biosciences files updated pro forma financials for Cernostics acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pro forma net loss of $38.9M for FY2021, including $3.6M in transaction accounting adjustments.","Pro forma revenue of $94.7M, reflecting Cernostics' $0.6M contribution.","Pro forma diluted loss per share of $1.55, compared to Castle standalone $1.24.","Pro forma operating loss of $47.7M, up from $40.1M standalone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369286,"accession_number":"0001447362-22-000083","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q1 revenue up 18% to $26.9M; net loss widens to $24.6M; raises 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $26.9M (+18% YoY); adjusted revenue $26.3M (+50% YoY); net loss ($24.6M) vs ($4.3M) prior year.","Total test reports 8,627 (+68% YoY); DecisionDx-Melanoma +48%, DecisionDx-SCC +117%.","2022 total revenue guidance raised to $118-123M from $115-120M.","Acquired AltheaDx/IDgenetix PGx test for mental health in April 2022; adds ~$5B TAM.","Operating cash flow ($21.4M) vs ($3.6M); adjusted EBITDA ($11.4M) vs $0.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":26852000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369285,"accession_number":"0001447362-22-000074","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Castle Biosciences completes AltheaDx acquisition; issues 763,887 shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$65M initial consideration: $32.5M cash and $32.5M in stock (763,887 shares).","Up to $75M in milestone payments through Dec 31, 2024; 50% cash, 50% stock.","Max shares issuable capped at 1,271,718; up to 507,831 more for milestones.","Shares unregistered under Section 4(a)(2)/Reg D; resale registration due in 40 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369284,"accession_number":"0001447362-22-000058","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-04-07T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Castle Biosciences signs 126-month lease for 44,677 sq ft Pittsburgh office/lab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial term of 126 months; first 36 months 20,856 sq ft, expanding to 44,677 sq ft from month 37.","Base rent: $3.62/sq ft/yr first six months, then $28.62–$34.84/sq ft/yr over term.","Landlord contributes up to $2.5M for leasehold improvements; company pays excess.","Company has option to extend lease for one additional five-year period at fair market rent subject to floor.","Early termination option after month 90 with $2.3M fee, subject to adjustment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369283,"accession_number":"0001140361-22-012901","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-04-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Castle Biosciences to acquire AltheaDx for $65M upfront plus up to $75M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration: $32.5M cash + $32.5M stock; milestone payments up to $75M tied to 2022-2024 revenue and Medicare coverage.","AltheaDx had <$1M revenue in 2021; its IDgenetix test focuses on mental health pharmacogenomics.","Expected Q2 2022 close; subject to AltheaDx stockholder approval and other customary conditions.","CEO Derek Maetzold and Chairman Daniel Bradbury are AltheaDx directors and beneficial owners, creating related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388482,"accession_number":"0001447362-22-000050","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Castle Biosciences expands Phoenix office by 5,904 sq ft, extends lease through 2033","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expanded premises include Suite 170, adding 5,904 rentable sq ft for total ~17,820 sq ft.","Lease term extended to 129 months following expansion completion; expiration approximately 2033.","Base rent starts at $21.00/sq ft/yr ($31,185/month) with annual $0.50/sq ft increases through ~2033.","Landlord provides $15.00/sq ft tenant improvement allowance ($88,560); Tenant pays any excess costs.","Parking rights increase to 65 total spaces, including 5 covered reserved spaces, at no additional charge."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388481,"accession_number":"0001447362-22-000043","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences FY2021 revenue $94.1M (+50% YoY); guides FY2022 $115-120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2021 revenue $94.1M, up 50% vs $62.6M in 2020; net loss $(31.3)M vs $(10.3)M.","Total GEP test volume 28,118 (+55% YoY); DecisionDx-Melanoma 20,328 (+25%).","Q4 revenue $25.0M (+45% YoY); delivered 8,242 test reports (+60%).","Cash and equivalents $330M at Dec. 31, 2021; adjusted EBITDA $(14.9)M for 2021.","FY2022 revenue expected $115-120M; includes TissueCypher Barrett's esophagus test."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":94085000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388478,"accession_number":"0001447362-22-000016","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K/A","filed_at":"2022-01-14T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Castle Biosciences acquires Cernostics for up to $30M upfront plus $50M earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Up-front consideration $30M (cash or cash/stock mix); earnouts up to $50M based on 2022 commercial milestones.","Cernostics 9M2021 revenue $469K, net loss $2.8M; 2020 revenue $141K, net loss $2.6M.","Cernostics' TissueCypher Barrett's Esophagus Assay added to Castle's diagnostics portfolio.","Transaction closed December 2021; amendment files required financial statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388480,"accession_number":"0001447362-22-000010","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences expects FY 2021 revenue to meet or exceed $89-93M guidance; test volumes up 55%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 revenue expected at or above guided $89-93M; year-end cash ~$330M.","Total gene expression profile test reports delivered in 2021: 28,118 (+55% YoY).","DecisionDx-Melanoma reports up 25% YoY to 20,328 despite 11% drop in melanoma diagnoses vs pre-COVID.","DecisionDx-SCC reports grew to 3,510 in 2021 from 485 in 2020; Q4 2021: 1,265 (+196%).","myPath/DecisionDx DiffDx-Melanoma reports: 2,662 in 2021 vs 73 in 2020; Q4: 904 vs 73."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":94085000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388479,"accession_number":"0001447362-22-000005","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Castle Biosciences Chief Business Officer resigns; enters consulting agreement with vesting extension","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bernhard Spiess resigns as CBO effective Dec 31, 2021; separation agreement signed Dec 29, 2021.","Receives accrued salary ($16,666.67), PTO payout ($72,783.74), and 2021 bonus (50% salary × board-approved corp attainment).","Consulting agreement at $250/hour through Dec 31, 2022; outstanding equity continues vesting during consulting term.","Non-competition for 1 year and non-solicitation for 3 years after consulting ends.","Company may terminate consulting agreement immediately for any reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406413,"accession_number":"0001140361-21-040395","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2021-12-06T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Castle Biosciences completes acquisition of Cernostics for $30M upfront cash, up to $50M earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed December 3, 2021; upfront cash consideration approximately $30 million.","Up to $50 million additional earnout payable in cash or stock upon achieving 2022 commercial milestones.","Merger agreement amended to cap stock issuance at 19.9% of outstanding shares for Nasdaq compliance.","Cernostics becomes wholly owned subsidiary; post-closing adjustments and escrow apply.","Financial statements of acquired business to be filed by amendment within 71 calendar days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406412,"accession_number":"0001447362-21-000262","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2021-12-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Castle Biosciences extends Phoenix office leases through April 2033, adds 2,564 sq ft","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3707 Lease amended: term extended 61 months to April 2033; premises expanded by 2,564 sq ft to 17,752 total.","Base rent at 3707 starts at $20.50/sq ft/year ($30,326.33/mo) with annual $0.50/sq ft increases.","3737 Lease amended: term extended 69 months to April 2033; base rent unchanged until Aug 2027 then $23.50/sq ft/year.","Rent abatement for first full calendar month after 3707 expansion commencement.","Lease amendments involve two properties with Landlord Alturas Siete I and II, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406411,"accession_number":"0001447362-21-000250","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Q3 revenue $23.5M (+54% YoY); guides FY21 $89-93M; acquiring Cernostics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $23.5M, up 54% vs $15.2M in Q3 2020; adjusted revenue $23.6M, up 71%.","Total test reports 7,727 (vs 4,779); DecisionDx-Melanoma 5,505 (+25%), DecisionDx-SCC 934.","Gross margin 77.9%; adjusted 80.9%; cash $363M as of Sept 30, 2021.","Signed definitive agreement to acquire Cernostics (TissueCypher BE test) to expand TAM by ~$1B; close expected by year-end 2021.","On track to meet raised FY21 revenue guidance of $89-93M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":69046000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406410,"accession_number":"0001447362-21-000239","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2021-10-19T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Castle Biosciences to acquire Cernostics for up to $80M; expands into GI diagnostics with TissueCypher","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration of $30M (cash or $20M cash + $10M stock at Castle's discretion); up to $50M in milestones based on 2022 performance.","Cernostics' TissueCypher Barrett's Esophagus Assay is first precision medicine test to predict progression to esophageal cancer in BE patients.","Deal expands Castle's estimated U.S. TAM by approximately $1B, complementing its dermatologic franchise.","Transaction expected to close prior to year-end 2021; Cernostics management to remain; operations stay in Pittsburgh."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425420,"accession_number":"0001447362-21-000215","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2021-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Castle Biosciences presents at Wells Fargo Healthcare Conference with slide deck","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Castle Biosciences presented at the 2021 Virtual Wells Fargo Healthcare Conference on September 9, 2021.","Slide deck attached as Exhibit 99.1 titled 'Transforming the management of dermatologic conditions'.","No specific financial or operational updates disclosed in the filing; full slide content not available.","This is a standard conference presentation, not a new material event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425419,"accession_number":"0001447362-21-000197","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q2 revenue $22.8M (+79% YoY); raises FY2021 guidance to $89-93M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $22.8M, up 79% YoY; adjusted revenue $22.9M, up 120% YoY excluding prior-period adjustments.","DecisionDx-Melanoma test reports up 70% YoY to 5,128; total dermatology test volume 6,539.","Full-year 2021 revenue guidance raised to $89-93M from prior $80-83M.","Acquired Myriad myPath Laboratory for $33M in May, adding myPath Melanoma test.","Cash at $368M; operating cash flow -$6.4M due to acquisition and Medicare advance recoupment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":45571000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425418,"accession_number":"0001447362-21-000166","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2021-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Castle Biosciences appoints Kimberlee Caple and Ellen Goldberg to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Kimberlee Caple as Class III director (term until 2022 annual meeting).","Appointed Ellen Goldberg as Class I director (term until 2023 annual meeting).","Each receives $40,000 annual cash, 5,365 stock options, and 1,320 RSUs per standard policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-07-16T23:59:59+00:00|425418"}